title: Proposal for a Council Recommendation on the suitability of blood and plasma donors and the screening of donated blood in the European Community

eurovoc_concepts:
blood transfusion
data protection
disease prevention
product safety
public health

text: COMMISSION OF THE EUROPEAN COMMUNITIES •ir -tr Brussels, 17. 11. 1997 C0M(97) 605 final 97/0315 (CNS) PROPOSAL FOR A COUNCIL RECOMMENDATION on the suitability of blood and plasma donors and the screening of donated blood in the European Community (presented by the Commission) Explanatory Memorandum 1. INTRODUCTION in to recommend, the European Commission 1. Continuing concerns about the quality, safety and efficacy of blood and blood products in the its European Community motivated Communication of December 1994 , the development of a Community blood strategy in order to improve confidence in the safety of the blood transfusion chain and to promote Community self- sufficiency, The Council in its Resolution of June 19952 invited the Commission to continue its efforts to define such a strategy using as a basis the activities it had proposed. In November 1996, Council's Resolution3 on a Strategy Towards Blood Safety and Self-sufficiency in the European Community further refined the constituent elements of the strategy by calling for a co ordinated approach to the safety of blood and blood products, and calling on the Commission to submit proposals as a matter of urgency, drawing upon the Conclusions and Recommendations of a Colloquium on blood safety and self-sufficiency held in Adare, Ireland. Responding to this invitation, the Commission has been pursuing activities to advance the development of this strategy and as a first step has concentrated on the need for common requirements regarding the suitability of blood and plasma donors and the testing of their donations. Such requirements can make a significant contribution to ensuring the quality and safety of needed blood and plasma, restoring the confidence of Community citizens in the blood transfusion system, and contributing to the continuing efforts to achieve Community self-sufficiency through voluntary unpaid donations. 2. THE BLOOD TRANSFUSION CHAIN 2. The blood transfusion chain comprises an extensive number of complex and interrelated activities extending from the willingness of an individual to provide blood or plasma for therapeutic use; through the elaborate precautions taken in the preparation of both labile blood components (red blood cells, white blood cells, platelets and plasma) and stable industrially- prepared derivatives (e. g. albumin, clotting factor concentrates, protease inhibitors and immunoglobulins); to the administration of any of these products to a patient and subsequent follow-up. Each of these steps requires meticulous attention to safety. 3. One of the most crucial links in this chain, however, are the requirements for ensuring the acceptance of an individual as a blood or plasma donor and those for testing the donated blood or plasma for infectious diseases. As the Commission noted in its 1994 Communication, the donor selection process differs across the Community and "it would be beneficial if an agreement is reached as regards the rules and practices for donor selection, including new and repeat donors as well as donors of whole blood, cellular components and plasma, to be applied across the Community". It also referred to the differing testing requirements that exist in the Communication from the Commission on Blood Safety and Self-sufficiency in the European Community. COM(94) 652 final. 21. 12. 1994. 23p. O. J. No C164. 30. 6. 95. p. 1 O. J. NoC374. 11. 12. 96. p. l Department of Health, Ireland. Conclusions and Recommendations. Colloquium on Blood Safety and Self- sufficiency: An Agenda for the European Community. Adare, County Limerick, Ireland. 4-6 September 1996. 1 Community hindering the transfer of blood and the free movement of blood products and impeding the goal of self-sufficiency in blood and plasma as starting material used for the preparation of medicinal products. These existing variations among the Member States of the European Community contribute to a lack of confidence not only among patients but among the blood establishments themselves. 4. Donor selection and the screening of donations were among the topics discussed at the Adare Colloquium by Member States experts who recommended, inter alia, that existing guidelines on donor selection be reviewed "with a view to making proposals for common criteria to be used in the European Community" and that "a minimal set of screening tests should apply in all Member States for the testing of whole blood and components for transfusion as well as plasma for fractionation". Moreover, they stressed the need for criteria at Community level regarding donor identification and determining the core elements and risk behaviours that should be identified through a donor screening questionnaire. 5. In order to establish the basis for common criteria, the Commission in early 1997 conducted a survey of the current regulations and practices in the Member States regarding the selection of donors and the screening of their blood donations. This survey addressed the current legislative requirements in the Member States and guidelines of the Council of Europe and the World Health Organization; the criteria for the selection of whole blood and plasma donors; elements covered in the donor questionnaire and physical examination; the major reasons for donor deferral for the safety of recipients; the current screening tests required for individual whole blood donations and plasma obtained through apheresis; and the interpretation of a reactive result in the initial screening test for infectious agents (e. g. HIV, HBV, HCV, syphilis) in relation to the clinical use of the donation. The outcome of the survey, which was discussed at a meeting of national experts in June 1997, and the deliberations at the meeting itself clearly reflected variations in regulations and practices in the-Member States. The results of the survey are being presented in a working paper of the Commission Services entitled "The suitability of blood and plasma donors and the screening of their donations: a 1997 survey of the regulations and practices in the Member States of the European Community". 3. EXISTING AND PROPOSED REQUIREMENTS 6. Directive 89/381 /EEC5 extended the scope of pharmaceutical legislation to encompass the quality, safety and efficacy requirements for industrially prepared medicinal products derived from blood and plasma but specifically excluded whole blood, plasma and blood cells of human origin. In respect of measures covered by the modification as to testing requirements, referred to in Article 6 of that Directive, to be taken by the Member States to prevent the transmission of infectious diseases by blood and plasma used as a starting material for the manufacture of medicinal products, Article 3 refers to the application of the monographs of the European Pharmacopoeia and to recommendations by the Council of Europe and the World Health Organization as regards in particular the selection and testing of blood and plasma donors. The Directive makes no provision for adaptation to requirements recommended or published on donor selection that may have arisen after its adoption in 1989 nor to scientific and technical progress. Moreover, since Article 1(2) of the Directive specifically excludes whole blood, plasma or blood cells of human origin from its scope, difficulties may arise in practice when the final destination of the donation is not known. O. J. No L181, 28. 6. 89, p. 44 7. Council Decision 94/358/EC6 accepted on behalf of the European Community, the Convention on the elaboration of a European Pharmacopoeia which aims to harmonise quality specifications for active substances and excipients in order to facilitate the free circulation of medicinal products in the countries party to the Pharmacopoeia. This harmonisation simplifies pharmaceutical and biological testing requirements for marketing authorisations. The European Pharmacopoeia's monograph on 'Human Plasma for Fractionation' makes only a reference to Council of Europe recommendations regarding the selection of donors which are therefore not mandatory. 8. Council Directive 95/46/EC addresses the protection of individuals with regard to the processing of personal data and the free movement of such data. This Directive requires that certain sensitive data in particular that related to the health of an individual be subject to reinforced protection. It covers only personal data and not that rendered anonymous so that the person is no longer identifiable. Processing of medical data is prohibited unless the data subject gives his explicit consent. This prohibition is not applicable, however, if the processing of the data is for the purpose of preventive medicine, medical diagnosis, the provision of care and treatment or the management of health services, and the- data are processed by a health professional subject to the obligations of professional secrecy. 9. At the level of the Member States, the Commission's survey highlighted the significant variations in legislative requirements regarding the selection of donors and the testing of donations. These range from extensive and detailed legislation developed in recent years, to regulations dating to 1980, to non-binding national guidelines. Legislative revisions in the area of blood are currently underway in two Member States. These variations hinder the transfer of blood (and plasma) and the free movement of blood and plasma products, thus impeding the achievement of Community self-sufficiency. lO. Therefore, in keeping with the goal of making a contribution towards ensuring a high level of health protection to the citizens of the Community, and providing for the attainment of self- sufficiency in blood and plasma through voluntary unpaid donations, and in view of the variations both in legislation and practice in the Member States, the Commission considers it imperative that common requirements be introduced by all Member States based on agreed recommendations. These should be based on the outcome of its survey and the latest scientific evidence regarding the determination of the suitability of donors and the screening of their donations. As stated in a recent report by the Swedish National Working Group on Blood Self- sufficiency8 "many European citizens do not trust the quality and safety of blood products originating from countries other than their own. Only by implementing common standards can we increase the trust between Community Member States, enhance the free movement of blood and blood products, and reach the goal of Community self-sufficiency". These requirements must, pursuant to Article 129 of the EC Treaty, be based on Council recommendations, which should aim at promoting sound practices and consistency throughout the Community without being disproportionate with regard to the overall objectives being pursued, namely the safety and sufficiency in the Community of blood and plasma and the health protection of the donors. To that end, the proposed recommendations should address donor suitability and eligibility, volumes collected, and the screening of samples of donated blood, and should be congruent with the provisions of Directive 89/3 81 /EEC. O. J. No L158, 25. 6. 94, p. 70. O. J. No L281. 23. 11. 95. p. 31 Swedish National Working Group on Blood Self-sufficiency. European self-sufficiency in blood and blood products: Balancing supply and demand. Background Paper to the statement by the Swedish Minister of Health and Social Affairs, Margot Wallstrom, (Health) Council Meeting, Luxembourg, June 5 1997. 6p. 3/H- 4. DONOR SUITABILITY 11. Ascertaining the suitability of an individual who has offered to donate blood or plasma is essential in order to ensure that there are no detrimental effects to the prospective donor's health and to protect that of future recipients of the blood products emanating from that donation. The initial step in this process is the provision of accurate and understandable information to the prospective donor about the benefits and hazards, both to their own health and that of future recipients, associated with blood and plasma donation. Agreement by the prospective donor of a willingness to proceed should be followed by the identification and registration of the donor, the recording of this information in an appropriate data file, the verification of certain physical parameters, and the compilation of a medical history to identify and screen out those who may be at some health risk either to themselves or to recipients of their donation. 12. Although the true effectiveness of written questionnaires in screening out donors with high risk behaviours has not yet been fully demonstrated, and the need for a Community-wide comprehensive and common questionnaire not established due especially to cultural differences in the Community, it is essential that several core elements and risk behaviours be addressed during the pre-donation process. These should be addressed in the written questionnaire, or the interview with a trained health care staff member, or both and should cover a number of diseases and conditions, as well as certain risk factors, on which there is solid scientific consensus for their inclusion. 13. Acceptance criteria for donors of whole blood and apheresis plasma should be clearly established to ensure that there are no detrimental effects to the donor's health and additional criteria need to be imposed for the protection of future recipients of the blood products deriving from their donation. Donors, who for one of many reasons may be deemed ineligible to donate blood either temporarily or permanently should be given appropriate counselling. The discretion of the physician is paramount in the final determination of eligibility of a donor. 5. DONOR INELIGIBILITY 14. A prospective donor may be considered ineligible to donate blood or plasma, either temporarily or permanently, at any time during the donation process. Such individuals are said to be "deferred" and the period of time during which they are considered ineligible varies according to different factors. It is important that appropriate records of such deferrals are maintained in such a way that while the confidentiality of the data is maintained, the information is accessible to authorised individuals whether at a donation site or when matters of safety are concerned. Such manual or computerised records are often referred to as donor deferral registers (DDR). 15. The survey of the requirements and practices in the Member States revealed general agreement regarding permanent deferral for particular situations such as HIV / AIDS, hepatitis C, syphilis, etc. Temporary deferral showed both commonality among Member States for some situations, and considerable variation for others. For example, temporary deferral ranged from 6 - 12 months for tattoos; 2 -5 years after recovery from tuberculosis; 1-2 years after recovery from toxoplasmosis; from "each service / doctor has own criteria" to 5 years for hepatitis A. These variations appear to reflect an absence of conclusive scientific data about the time frame for deferral of donors on which sound decisions can be made. Supplementary survey information submitted to the Commission following the meeting of experts also reflected the variations in practices. In order to arrive at suggested common criteria, therefore, a mean time frame of the, 5 responses received is proposed. The scientific basis upon which these deferral periods are made must be kept under review. 16. 1n those situations where a donor is deferred temporarily, provisions must be made to allow him / her to be considered for donation again at the end of the deferral period. 6. DATA PROTECTION 17. Although the measures taken by Member States to ensure the protection of data related to a blood or plasma donor were not addressed in the Commission survey, relevant requirements are laid down in Directive 95/46/EC. Measures to ensure positive donor identification, the verification of data, safeguards against unauthorised access to information, data additions, deletions or modifications, data irregularities and discrepancies and the security of confidential data all need to be taken into account. This is particularly applicable in cases where an individual is deferred. 18. Article 8 of the Directive refers to the processing of special categories of data including that concerning health. According to this Article, the processing of such data shall be prohibited in the Member States. It establishes, however, certain cases in which this prohibition shall not apply such as when the data subject has given his / her explicit consent to the processing of those data, when the data processing is required for the purposes of preventive medicine, medical diagnosis, the provision of care or treatment or the management of health care services, and where those data are processed by a health professional subject under national law or rules established by national competent bodies to the obligation of professional secrecy or by another person also subject to an equivalent obligation. The Article also establishes that Member States may, for reasons of substantial public interest, lay down exemptions to the prohibition with such measures notifiable to the Commission. 7. VOLUMES COLLECTED 19. The maximum amount of whole blood or plasma collected from a donor at any one sitting and over a 12 month period, the time interval between the donations, and the allowable frequency over a given time period have been established in order to prevent any adverse effects to the health of the donor as a consequence of the donation. For whole blood, the maximum volume collected during an individual donation (450 ml ± 10%) and the minimum time interval between donations (8 weeks) are practically the same in all the Member States and are in keeping with recommendations of the Council of Europe (1997) and the World Health Organization (1994). Two Member States as well as the standards of the American Association of Blood Banks (AABB), however, permit a higher volume (500- 525 ml). 20. For apheresis plasma, the maximum volume collected during an individual donation and over a 12 month period varies among the Member States - from 550 to 650 ml per donation; 0. 5 to 1 litre per week; and 10 to 25 litres per year. The frequency of donations varies between twice per week and twice a month and the maximum number of donations varies between 4 and 50 per year. This wide variation may be attributed in part to the differences between manual and automated plasmapheresis. 21. As a significant volume of plasma and plasma products, sourced from donors who are paid, is imported into the Community from the United States of America, it has to be noted that the allowable maximum plasma volume per individual donation, and over a 12 month time frame, 6 are higher in the USA than those currently permitted in several Member States. The maximum volume of plasma allowed per donation in the USA depends in practice on the weight of the donor: 625 ml for donors weighing between 50-67 kg; 750 ml for donors weighing between 68-79 kg; and 800 ml for those weighing 80 kg or more. 22. According to the 1997 report of the Swedish National Working Group on Blood Self- sufficiency, "the volume of plasma collected is based mainly on theoretical calculations about how much fluid can be lost without risk to the donor. In the US where the body size of the donor is used to determine the allowable volume, the donor's blood status has been systematically monitored without detecting disturbances. " 23. In view of the Community's goal of self-sufficiency and the lack of progress towards it, serious consideration has to be given to allowing an increase in the maximum allowable volumes of plasma currently prevailing in the Member States. This would contribute to the goal of self-sufficiency. The view espoused by some that higher volumes are detrimental to the health of the donor does not appear to be substantiated by scientific evidence. On the contrary, the United States Department of Health and Human Services stated in 1992 in a memo9 to licensed source plasma establishments that "An analysis based on comparison between the allowable volume of source plasma derived from whole blood collected during manual plasmapheresis and the experience to date with all of the approved equipment (automated plasma collection devices) indicates that there is no discernible impact on donor safety, or product quality with the use of the current limits in preference to any other". 24. Until scientific evidence is adduced to show that permitting an increase in the volume of blood or plasma collected from a donor or reducing the time interval between donations has a detrimental effect on the donor's health, and in view of the benefits for Community self- sufficiency, it is proposed that increased volumes such as those accepted in the United States scheme be recommended for application by the Member States. Programmes using increased volumes should be monitored closely to ensure that no detrimental effects accrue to the donor. 8. SCREENING OF SAMPLES OF DONATED BLOOD 25. Whether it is a donation of whole blood or components intended for transfusion purposes or plasma collected through apheresis and intended for transfusion or further manufacturing into medicinal products, sample specimens of the blood taken from the donor at the time of collecting the blood and plasma should be tested for markers of infections that can be transmitted to recipients. In order that the citizens of the Community have the highest degree of confidence in the safety of the blood and blood products administered for therapy, Member States should apply the same screening tests to the common source for both whole blood and components used for transfusion,and plasma used for fractionation with one exception, namely when plasma is collected by plasmapheresis for the sole purpose of fractionation some tests may not be required because the virus is not transmitted by plasma-derived products. 26. The survey showed that whether the donation is of whole blood or plasma, almost all Member States require a sample of the donor's blood to be tested for antibodies against the hepatitis C virus (anti-HCV), antibodies against the human immunodeficiency virus type 1 and 2 (anti- Department of Health and Human Services. FDA. Memo to All licensed Source Plasma Establishments. 4 November 1992. 7 this reflects the mandatory HIV 1 and 2), the surface antigen of the hepatitis B virus (HBsAg), and syphilis. With the exception of syphilis, the European Pharmacopoeia monograph on 'Human Plasma for Fractionation' for all blood and plasma donations used as source material for the preparation of industrially manufactured medicinal products. As syphilis is not transmissible by plasma-derived products, the Biotechnology Working Party of the Committee for Proprietary Medicinal Products (CPMP) advised in 1995 that this test is not required for plasma for fractionation. Only one Member State does not test for syphilis. requirements of 27. Requirements for other tests for markers of various diseases transmissible by blood transfusion vary among the Member States. A malaria test is generally not required but five Member States allow for it "when required" or required "for travellers to endemic areas". Testing for antibodies to human T-cell lymphotropic virus (anti-HTLV I and II) is carried out in six Member States with one indicating that it is carried out on first time donors and another reporting that although not required it is done. Testing for hepatitis B core antibodies (anti- HBc) is carried out in five Member States for whole blood donations with three requiring it only for first time donors. HIV p24 antigen test is not required in any of the Member States but is a pilot project in one. Only one Member State requires neopterin testing for whole blood donations. 28. The survey substantiated earlier reports regarding tests that are required in some Member States and not in others leading to impediments on the utilisation of excess plasma, the free movement of plasma-derived products, and therefore to a lack of progress towards Community self-sufficiency. This difficulty arises particularly with reference to alanine aminotransferase (ALT) which is not required by the European Pharmacopoeia. Plasma collected by some Member States that has not undergone this test is rejected for use by others. It is noteworthy that an expert panel at the National Institute of Health of the United States recommended that its use be discontinued since, as shown by scientific data, it had outlived its usefulness and was of little value now given the availability of the HCV test. This view was reiterated by the experts to the Adare Colloquium who considered that ALT screening had become redundant because of the specific screening for HBsAG and antibodies to hepatitis C. 29. lt follows from the above that a set of scientifically-based and broadly-supported requirements, as well as a procedure for making decisions, depending on the results of the various tests that donated blood undergoes, should be established based on agreed recommendations for the Community. 9. COMMON TERMINOLOGY the testing of donations 30. A fundamental requirement for arriving at common criteria related to the suitability of donors and terminology. Confusion and misunderstandings often arise as a result of different interpretations of the same terminology. In spite of the existence of several glossaries, there is still no consistent use of several terms in this sector such as blood products, repeat donors, etc. Therefore common terminology for use throughout the Community is proposed. the use of common is 10 DGIII/5941/94. "Selection and screening of donors for blood / plasma as starting material for medicinal products. Position paper for CPMP on harmonisation of selection and screening of donors/exclusion criteria" in"Inventory of Provisions relating to Medicinal Products Derived from Human Blood or Plasma", Brussels, March 1995. 10. SCIENTIFIC COMMITTEE AND REPORTING 31. The dynamic and rapidly-evolving environment of transfusion medicine, such as cytapheresis, total blood apheresis and cord blood collection as well as the questions posed by the availability or introduction of new technologies such as genome amplification technology (GAT) - a highly sensitive technique capable of detecting viral genomes even when serological tests are negative - as a possible screening test, demands that mechanisms be in place for the Community to have ready access to scientific and technical guidance and be able to respond quickly to changing technology and scientific information. Consideration will be given by the Commission to establishing a Scientific Committee on blood to advise it on these and the other matters covered in the proposed recommendation. 32. Moreover, in order to ensure that all Member States are fully aware of developments that have implications at Community level and to keep the Council informed of the measures that have been taken towards the implementation of common criteria in the Community, the Commission could prepare reports as appropriate. PROPOSAL FOR A COUNCIL RECOMMENDATION on the suitability of blood and plasma donors and the screening of donated blood in the European Community \p THE COUNCIL OF THE EUROPEAN UNION Having regard to the Treaty establishing the European Community, and in particular Article 129 thereof; Having regard to the proposal from the Commission ; Having regard to the opinion of the European Parliament, 1. Whereas in accordance with point (o) of Article 3 of the Treaty, Community action must include a contribution towards the attainment of a high level of health protection; 2. Whereas the Commission's Communication on Blood Safety and Self-sufficiency in the European Community of December 1994 identified the need for a blood strategy in order to reinforce confidence in the safety of the blood transfusion chain and promote Community self- sufficiency; 3. Whereas Council in its Resolution of 2 June 1995 , in response to the Commission's Communication, invited it to submit appropriate proposals in the framework of development of a blood strategy; 4. Whereas Council in its Resolution of 12 November 1996 on a strategy towards blood safety and self-sufficiency in the European Community invited the Commission to submit proposals as a matter of urgency with the view to encouraging the development of a co-ordinated approach to the safety of blood and blood products; 5. Whereas the European Parliament in its resolutions on blood safety and self-sufficiency through voluntary unpaid donations in the European Community has stressed the importance of ensuring the highest level of safety in the selection of donors and the testing of donations and has reiterated its continued support for the objective of Community self-sufficiency; 6. Whereas Council Directive 89/381/EEC extended the scope of pharmaceutical legislation to guarantee the quality, safety, and efficacy of proprietary industrially prepared medicinal products derived from human blood or human plasma; whereas it does not apply to whole blood, to plasma, or to blood cells of human origin; i. 2 3 4 5 6 7 8 9 10 O. J. O. J. COM (94)652 final. Brussels. 21. 12. 1994 O. J. No C164, 30. 6. 95, p. l O. J. NoC374, U. 12. 96, p. l O. J. NoC268, 4. 10. 93, p. 29 O. J. NoC329, 6. 12. 93, p. 268 O. J. No C249, 25. 9. 95, p. 231 O. J. NoC141. 13 5. 96. p. 131 O. J. No L181, 28. 6. 89, p. 44 It 7. Whereas therapeutic use of blood and medicinal products derived from human blood and plasma contributes significantly to saving lives and yields considerable benefits for those suffering from long term blood disorders; whereas, however, in spite of their significant therapeutic value, blood, blood components, and blood and plasma derivatives have the potential to transmit infectious diseases; 8. Whereas the availability of blood and plasma used for therapeutic purposes and as starting material for the manufacture of medicinal products is dependent on the willingness and generosity of Community citizens who are prepared to donate; 9. Whereas donations should be voluntary and unpaid; 10. Whereas in respect of blood or plasma as a starting material for the manufacture of proprietary medicinal products, Article 3 of Council Directive 89/381/EEC refers to measures: covered by the modification, as to testing requirements, referred to in Article 6 of that Directive, to be taken by Member States to prevent the transmission of infectious diseases, comprising the application of the monographs of the European Pharmacopoeia and the recommendations of the Council of Europe and the World Health Organization as regards in particular the selection and testing of blood and plasma donors; to promote Community self-sufficiency in human blood or human plasma; and to encourage voluntary unpaid donations of blood and plasma; 11. Whereas it is not always possible to know at the time of whole blood or plasma collection which donation may be used for further manufacture rather than used in transfusion; 12. Whereas all blood and plasma used for therapeutic purposes, whether for transfusion or for further manufacture into industrially-prepared medicinal products, should be obtained from individuals whose health status is such as to ensure that transmission of disease does not take place, and that each and every blood donation should be tested in accordance with rules which provide assurances that all necessary measures have been taken to safeguard the health of Community citizens who are the recipients of blood and blood products; 13. Whereas given that the blood transfusion systems in the Member States of the European Community exist to serve its citizens, it is necessary to secure their confidence in the safety of these systems; 14. Whereas disparities in policies and practices among the Member States regarding the selection of donors and the screening of donations within the Community are such as to undermine confidence among its citizens as well as blood transfusion services in the safety of the blood and blood products and hinder the achievement of self-sufficiency; 12 15. Whereas the goal of Community self-sufficiency can only be achieved through co-operation among the Member States in order to overcome such disparities and build mutual confidence in all aspects of safety of the blood transfusion chain; 16. Whereas the suitability of an individual to donate blood and plasma is an essential component in contributing to the safety of blood and blood products and to the goal of self-sufficiency; 17. Whereas it is essential that all measures be taken to safeguard the health of those who provide their blood and plasma and to minimise the hazard of transmission of infectious diseases by blood or blood products; 18. Whereas uniformity and consistency throughout the Community in the acceptance of donors, the screening of donations and the recording of relevant data will help to contribute to the achievement of self-sufficiency and to increasing confidence in the safety of blood and plasma donations and the transfusion process; whereas in order to bring about such uniformity and consistency, and build confidence, measures are required at Community level; 19. Whereas measures at Community level should take into account existing guidelines, recommendations and standards in the area of blood at both national and international levels; 20. Whereas in accordance with the principle of subsidiarity, any new measure taken in an area which does not fall within the exclusive competence of the Community, such as donor suitability and testing of donations, may be taken up by the Community only if, by reason of the scale or effects of the proposed action, the objectives of the proposed action can be better achieved by the Community than by Member States; Whereas commonly agreed requirements on donor suitability and testing of donations need, therefore, to be introduced in order to contribute to the safety of donated blood and plasma and the health protection of donors and to permit confidence in safety of the transfusion chain among citizens, especially as they move about in the Community, and to contribute to the attainment of Community self- sufficiency as provided for in Community legislation; 21. Whereas in accordance with the principle of proportionality, the means to be deployed at Community level for promoting sound practices and consistency throughout the Community in the suitability of blood and plasma donors and the screening of donated blood must be in proportion to the objective pursued; 22. Whereas recommendations by the Council, pursuant to Article 129 of the EC Treaty, are the appropriate means for doing so at Community level; whereas such recommendations must be congruent with the provisions of Directive 89/381/EEC; 13 23. Whereas recommendations on donor suitability and testing requirements form part of a strategy to enhance safety of thé blood transfusion chain, the other elements of which include the inspection and accreditation of blood collection establishments, requirements related to quality assurance of the processes involved, the optimal use of blood and blood products, haemovigilance, and public awareness; 24. Whereas it is necessary that the best possible scientific advice is available to the Community in relation to the safety of blood and blood products; 25. Whereas Directive 95/46/ËC11 on the protection of individuals with regard to the processing of personal data and the free movement of such data lays down special requirements for the processing of data concerning health; HEREBY RECOMMENDS" THAT 1. DEFINITIONS For the purpose of this Recommendation, Member States assign to the terms listed in Annex 1 the meaning given to them therein; 2. PROVISION OF INFORMATION TO PROSPECTIVE DONORS Member States provide to all prospective donors of blood or plasma: 2. 1 For donor awareness a. Accurate but generally understandable educational materials about the essential nature of blood, the products derived from it, and the important benefits to patients of blood and plasma donations; b. The reasons for requiring a medical history, physical examination, and the testing of donations; information on the risk of infectious diseases that may be transmitted by blood and blood products; the signs and symptoms of AIDS, and the significance of 'informed consent', self-deferral, and temporary and permanent deferral; c. The reasons why they should not donate which may be detrimental to their own health; d. The reasons why they should not donate which put recipients at risk, such as unsafe sexual behaviour, HIV /AIDS, hepatitis, drug addiction and the use and abuse of drugs; e. The option of changing their mind about donating prior to proceeding further without any undue embarrassment or discomfort; 11 O. J. No L281, 23. 11. 95, p. 31 14 f. Information on the possibility of withdrawing or self-deferring at any time during the donation process; g. The opportunity to ask questions at any time; h. The undertaking that if test results shows evidence of any pathology, they will be contacted by the blood collection centre; i. Specific information on the nature of the procedures involved in the donation process and associated risks for those willing to participate in apheresis programmes, whether for plasma or cellular components. 2. 2 Confidentiality a. The measures taken to ensure the confidentiality of: any health-related information provided to the authorised health personnel, the results of the tests on their donations, as well as any future traceability of their donation; b. The assurance that all interviews with prospective donors are carried out in private; c. The option of requesting the medical staff of the blood collection centre not to use his / her donation. 3. INFORMATION REQUIRED FROM PROSPECTIVE DONORS Member States ensure that, upon agreement of a willingness to proceed to donate blood or plasma, all prospective donors (whether first time, new, repeat or regular) provide to the blood and plasma collection establishment: 3. 1 Identification Identification, supported by valid official documentation providing name (first and surname), address, and date of birth. 3. 2 Health history a. Information on their health and medical history including any relevant social and behavioural characteristics that may assist in identifying and screening out persons whose donation could present a higher risk of transmitting infections as well as those who could have contracted a recent infection that may not yet be detectable in the screening tests; b. Answers to questions about their health and medical history by way of a written questionnaire and a personal interview with a trained health care staff member which should address the elements and risk behaviours listed in Annex 2: c. Their signature and that of the health care staff member conducting the interviews on the donor questionnaire acknowledging that the educational materials provided have been read 15 and understood, the opportunity to ask questions has been presented, and satisfactory responses have been received; 3. 3 Informed consent a. Their informed consent in writing that they wish to proceed with the donation process; b. The prospective donor's agreement that if their blood or plasma donation becomes excess to the needs of their own Member State, it may be shared with another Member State of the Community that is in need ; 4. REGISTRATION OF DONOR Member States, in order to facilitate future verification of repeat and regular donors, future tracing of donations, and future exchanges of information* establish a mutually compatible donor identification / registration system to: 4. 1 Donor centre identification a. Permit every donation centre in each Member State to be uniquely identified, by communicating to all other Member States and to the Commission a list of centres and their identification comprising the country code and a suitable combination of letters and numbers at their discretion; 4. 2 Donor identification and registry a. Require that all relevant information regarding the identification of prospective donors be recorded in an automated or manual system for new and first time donors and be verified prior to each donation for repeat and regular donors; b. Provide for the keeping of records on donors and prospective donors in such a way as to ensure unique identification, protect the identity of the donor from unauthorised access to confidential information, but facilitate future traceability of any donation; c. Allow for the inclusion of information related to adverse donor reaction to the donation, reasons for preventing an individual from donating, whether on a temporary or permanent basis while ensuring confidentiality. 5. DONOR SUITABILITY Member States, in order to ensure the suitability of individuals to be accepted as donors of blood and plasma: 5. 1 Suitability criteria for the acceptance of whole blood and apheresis plasma donors a. Ensure that general criteria for the acceptance of blood and plasma donors are clearly spelt out in every donation centre and that clear messages are presented to donors as to the importance of their willingness to donate but also the importance of the acceptance criteria; 16 b. Ensure that the responses given to the issues raised in the written questionnaire and / or the personal interview, as presented in Annex 2, provide the necessary confidence that the donation will not adversely affect the health of a future recipient of the products derived from that donation; c. Ensure that the prospective donor meets the physical requirements criteria contained in Annex 3 in order that there are no detrimental effects to his / her own health as the result of the donation; d. Ensure that the prospective donor's suitability is determined at each donation session; e. Prohibit or phase out the practice of using'replacement donors'; f. Require the responsible physician to give his / her written authorisation as to the final determination of the suitability of a prospective donor, when this may be questionable. 6. DONOR INELIGIBILITY Member States, in order to ensure that the prospective donors do not cause harm to their own health nor that their donation present a risk of transmission of infectious diseases: 6. 1 Deferral criteria for whole blood and apheresis plasma donors a. Ensure those who may show evidence of one of the characteristics listed in Annexes 4 and ' , 5 should be rendered either permanently or temporarily ineligible to donate blood and plasma; b. Ensure that appropriate provisions are in place in the donation centre for counselling, as appropriate, to prospective donors who are deferred. 6. 2 Deferral registers a. Maintain a record of any prospective donor deferral, whether permanent or temporary, including the reasons why; b. Ensure that such donor deferral registers are set up so as to fully respect data confidentiality requirements but be available for consultation by authorised personnel of the blood collection establishment or appropriate authorities when matters of safety are concerned. 7. DATA PROTECTION Member States, in order to ensure the confidentiality of sensitive medical information about prospective donors: a. Ensure that measures are in place for prospective donor identification and accurate data verification; 17 b. Ensure that data security measures are in place as well as safeguards against unauthorised data additions, deletions or modifications to donor files or deferral registers, and transfer of information; c. Ensure that procedures are in place to resolve data discrepancies; d. Prevent the unauthorised disclosure of such information, while ensuring the traceability of donations; e. Pay particular attention to compliance with the requirements of Directive 95/46/EC in particular its Article 8, when processing data related to blood and plasma donors. 8. VOLUMES COLLECTED FOR SAFETY OF DONOR To protect the health of the donor, Member States: a. Adhere to the maximum volumes of blood and plasma collected at a single donation and over a 12 month period presented in Annex 6; b. Adhere to the minimum time intervals between donations as presented in Annex 6; c. Ensure that medical attention is available to the donor in the event of an adverse event related to the donation. 9. TESTING SAMPLES OF DONATED BLOOD Member States, in order to ensure the safety of all blood and plasma donations: a. Ensure that a sample of all donations whether intended for transfusion purposes or for further manufacturing into industrially prepared medicinal products is tested for diseases transmissible by blood using licensed screening tests to eliminate units that are repeat reactive; b. Ensure that all blood donations be found non-reactive for the transmissible disease markers listed in Annex 7; c. Require re-testing of the blood samples found to be reactive in an initial screening test in accordance with the general algorithm set out in Annex 8; 10. ADDITIONAL MEASURES a. Member States take the necessary steps for the dissemination of this recommendation to all parties concerned, and in particular to blood establishments in their territory; b. Member States take all necessary measures to encourage the voluntary and unpaid donation of blood or plasma; INVITES THE COMMISSION To report on the application of these recommendations and keep the matters covered therein under review in order to take the necessary steps for revision and updating. Done at Brussels g F or t he Council The President ANNEX 1 Common Terminology Blood Blood product Blood component Whole blood collected from a single donor and processed either for transfusion or further manufacturing Any therapeutic product derived from human whole blood or plasma donations. Therapeutic components of blood (red cells, white cells, plasma, platelets) that can be prepared by centrifugation, filtration, and freezing using conventional blood bank methodology. Plasma derivative Highly purified human plasma protein prepared under licensed pharmaceutical manufacturing conditions Cell-derivative Donor A therapeutic product derived from a blood component (as derived from leukocytes - interferon, cytokines - or from outdated erythrocytes - haemoglobin solution) First time donor Someone who has never donated either blood or plasma. Deferred donor Someone who, for protection of their own health or that of potential recipients of blood products prepared from his / her donation, is not permitted to give blood or plasma. Lapsed donor New donor Someone who routinely had donated blood or plasma (regular donor) and has stopped presenting himself / herself to donate. Someone who has not donated blood or plasma within the last year or is not listed in the local donor registry. Prospective donor Someone who presents himself / herself at a blood or plasma collection establishment and states his / her wish to give blood or plasma. Repeat donor Regular donor Someone who has donated before and within the last year in the same donation centre. Someone who routinely donates their blood or plasma at the permissible time intervals. Replacement donor Donors recruited by patients to enable them to undergo elective surgery. Medicinal product derived from blood or plasma Same meaning as in Directive 89/381/EEC Suitability Process by which an acceptance decision of a prospective blood or plasma donor can be made. Personal data Any information relating to an identified or identifiable natural person who can be identified, directly or indirectly, in particular by reference to an identification number or to one or more factors to his physical, physiological, mental, economic, cultural or social identity. (Directive 95/46/EC) Voluntary, unpaid blood donation Same meaning as in Directive 89/3 81/EEC l9 ANNEX2 Common Elements to be Covered in a Donor Questionnaire Indication that the questionnaire is to be completed, signed and dated General health of the donor Whether prospective donor has recently consulted a doctor is taking any medication has haemophilia or related blood clotting disorders participates in hazardous sports (e. g. motor racing) undertakes employment that might cause problems within 24 hours after blood donation is pregnant or has delivered a child now under 1 year (for women) has received growth hormone or pituitary extract treatment has received a blood transfusion has had a corneal or dura mater transplant has undergone tattooing, acupuncture, body piercing by someone other than qualified and / or licensed professional has been in recent contact (<3 weeks) with contagious infections, chicken pox, measles has recently received a vaccination(polio, tetanus, holiday vaccinations) has recently (<5 days) ingested aspirin (or other pain killers) is working as a prostitute is HIV positive has a spouse who is HIV positive has a family history of Creutzfeldt-Jacob disease (CJD) self-injects drugs Whether prospective donor has / had Brucellosis Epilepsy Hepatitis Jaundice Major surgery/serious illness Malaria « Whether prospective donor has travelled • Outside Western Europe & North America • Men who have sex with other men • Sexual activity in Africa • Sexual activity in countries other than those in Africa: (to specify country) • Self-exclusion option The questionnaire has to be given and completed at every visit. 2o ANNEX3 Common Acceptance Criteria for Blood and Plasma Donors Age Blood and plasma donors should be 18 - 65 years of age. Acceptance of first time donors age 60 - 65 is at the discretion of the responsible physician. Repeat donors may continue to donate after the age of 65 with the permission of the responsible physician given annually. For whole blood, donors aged 17, and not legally classified as minors, may be accepted; otherwise written consent should be required according to applicable law. Body weight Donors weighing no less than 50 kg may donate whole blood or plasma. Blood pressure The systolic blood pressure should not exceed 180 mm of mercury and the diastolic pressure should not exceed 100 mm of mercury. Pulse The pulse should be regular and between 50 - 110 beats per minute. Those prospective donors who undergo intensive sport training and have a pulse rate lower than 50 beats per minute may be accepted. Haemoglobin The haemoglobin concentration should be determined prior to donation and shall be no less than 12. 5 g/100 ml for females and 13. 5 g/100 ml for males (or equivalent values expressed in mmol / 1). For apheresis plasma donors, the minimum shall be 12. 5 g/100 ml for both males and females. Haematocrit The packed cell volume (haematocrit) should be determined prior to donation and shall be no less than 38% for females and 40% for males. For apheresis plasma donors, the minimum shall be 38%. Donation interval For whole blood, the time interval between donations should be greater than 8 weeks. For apheresis plasma, this interval should not be less than 72 hours. Donation frequency For whole blood, the maximum number of times allowable for donations should be 6 / year for men, 4 / year for women and 3 / year for pre-menopausal donors. For apheresis plasma, the maximum donation frequency should be twice per week, Z\ ANNEX4 Common Deferral Criteria for Blood and Plasma Donors (For protection of donor) 1. Permanent deferral Prospective donors with any or a history of any of the following should be declared permanently ineligible to donate blood or plasma for the protection of their own health: • Auto-immune diseases • Cardiovascular diseases • Central nervous system diseases • Malignant diseases • Abnormal bleeding tendency • Fainting spells (syncope) or convulsions Permanent deferral in cases where prospective donors have or have had a severe or chronic gastrointestinal, haematological, metabolic, respiratory, or renal disease, not included in the preceding categories, should be determined by a qualified physician in the blood collection establishment. 2. Temporary deferral Ineligible for 1 year • Abortion • Pregnancy (after delivery) NOTE: Additional reasons may exist for the temporary deferral of a donor for the protection of their own health. A decision as to length of time is at the discretion of a qualified physician in the blood collection establishment. IX ANNEX 5 Common Deferral Criteria for Blood and Plasma Donors (For protection of recipient) 1. Permanent deferral Prospective donors with any, or a history of any, of ineligible to donate blood or plasma for the protection of potential recipients. the following should be declared permanently • Auto-immune diseases • Infectious diseases- persons suffering or having suffered from Babesiosis Brucellosis Creutzfeldt Jacob disease (CJD) (persons in whose family this has occurred) Hepatitis B (HBsAg confirmed positive) Hepatitis C Hepatitis, infectious (of unexplained aetiology) HIV/AIDS H T L V I / II Leprosy Kala Azar (leishmaniasis) Q fever Syphilis Trypanosoma cruzi (Chagas' disease) • Malignant diseases Alcoholic, chronic Cornea / dura mater transplantation recipient Intravenous (IV) drug use Males who have sex with other males Pituitary hormone of human origin (e. g. growth hormone) recipient Prostitutes (male and female) 2. Temporary deferral Prospective donors with any of the following conditions should be declared ineligible to donate blood or plasma temporarily. The time interval for deferral varies according to the condition. 2. 1 Ineligible for 3 years • Tuberculosis (after recovery) 2. 2 Ineligible for 1 year Accidental exposure to blood or blood contaminated instruments Acupuncture (if not performed by a qualified physician) Blood transfusion recipient Body piercing Drug allergy (after last exposure) Tattoo Toxoplasmosis (after recovery) Individuals who have had sexual relations with someone infected or at increased risk of infection with HBV, HCV, HIV 23 2. 3 Ineligible for 6 months • Mononucleosis infectiosa (after recovery) • Surgery, major 2. 4 Ineligible for 4 weeks • Following administration of live attenuated viral vaccines 2. 5 Ineligible for 48 hours • Following administration of killed / inactivated viral / bacterial and rickettsial vaccines • Following administration of vaccines (desensitising) • Rabies vaccine (prophylactic administration) 2. 6 Ineligible (time frame variable) • Hepatitis A • Malaria (does not apply to plasmapheresis donors) • Prescribed medicines • Tropical diseases (other) NOTE: Additional reasons may exist for the temporary deferral of a donor for the protection of the recipient. A decision as to length of time is at the discretion of a qualified physician in the blood collection establishment. H ANNEX 6 Common Volumes to be collected and time intervals for whole blood and plasma donations Whole Blood Maximum Volume per donation per consecutive 12 month period Minimum time interval between donations Maximum number of donations per 12 month period Automated plasmapheresis Maximum Volume per donation Donor Weight 50-67 kg 68-79 kg 80 kg or more Minimum time interval between donations Maximum number of donations per 7 day period 500 ml 3 litres 8 weeks 6 (males) 4 (females) (3 for pre-menopausal women) Volume Collected (excluding anticoagulant) 625 ml 750 ml 800 ml 72 hours 2 2s ANNEX 7 Common Testing Requirements for all Blood Samples whether a whole blood or plasma donation For all blood and plasma donations Antibodies to the Hepatitis C virus Anti-HCV Antibodies to the human immunodeficiency virus 1 Anti-HIV 1 Antibodies to the human immunodeficiency virus 2 Anti-HIV 2 Surface antigen of Hepatitis B HBsAg In addition For all, excluding plasmapheresis intended only for fractionation. ABO group Rhtype Malaria Treponema pallidum (syphilis) for travellers to endemic areas 2& ANNEX 8 Common Algorithm for Interpretation of reactive results in screening tests in relation to clinical use of donation and Reactive results in supplementary / confirmation tests in relation to donor deferral blood sample 1 x screening test screening test reactive/doubtful ± ± screening test \J/ unit/ donor cleared vr all tests negative donor cleared ± all tests negative" | donor cleared ^ negative donor and donation cleared 2 repeats of the same test kit ± screening test + + ± M/ screening test + ? ± eliminate unit ± screening test + /? ± 2 repeats of the screening test from another manufacturer v ± one of tests doubtful or positive ± in case of positive/doubtful or lacking result, plasma processing establishment to be informed about previous donations within 7 days ^ 2nd blood sample different screening tests X ± doubtful ± exclude/inform donor \k further clarification test positive ± ± ± look back exclude/inform donor x\ FINANCIAL STATEMENT PROPOSAL FOR A COUNCIL RECOMMENDATION ON THE SUITABILITY OF BLOOD AND PLASMA DONORS AND THE SCREENING OF DONATED BLOOD IN THE EUROPEAN COMMUNITY The proposal for a draft Recommendation on the suitability of blood and plasma donors and the screening of donated blood in the European Community has no financial impact either on the operational budget or on any human or administrative expenses. 2& IMPACT ASSESSMENT FORM ON COMPETITIVENESS AND EMPLOYMENT PROPOSAL FOR A COUNCIL RECOMMENDATION ON THE SUITABILITY OF BLOOD AND PLASMA DONORS AND THE SCREENING OF DONATED BLOOD IN THE EUROPEAN COMMUNITY The proposal for a draft Recommendation on the suitability of blood and plasma donors and the screening of donated blood in the European Community has no impact on competitiveness and employment. l°l ISSN 0254-1475 COM(97) 605 final DOCUMENTS EN 05 15 Catalogue number : CB-CO-97-617-EN-C ISBN 92-78-27583-2 Office for Official Publications of the European Communities L-2985 Luxembourg 3D


title: SCHRIFTELIJKE VRAAG nr. 3740/97 van Roberta ANGELILLI aan de Commissie. Milieueffectrapportage voor de aanleg van een tunnel onder de Engelenburcht in Rome

eurovoc_concepts:
European Investment Bank
Latium
engineering structure
environmental impact
financing plan
project evaluation
public works
underground railway
underground transport
urban construction

formats: html pdf print

text: 8. 6. 98 NL Publicatieblad van de Europese Gemeenschappen C 174/111 (98/C 174/171) SCHRIFTELIJKE VRAAG E-3735/97 van Yves Verwaerde (PPE) aan de Commissie (21 november 1997) Betreft: JEM-programma Kan de Europese Commissie me een eerste overzicht van de resultaten van het uitwisselingsprogramma voor jonge bedrijfsleiders geven, en meer bepaald: 1. het aantal kandidaten dat deelgenomen heeft aan de uitwisselingen tussen de Europese Unie en de Aziatische landen, in de twee richtingen, sinds het programma bestaat? 2. het aantal bedrijven dat deelnemers opgenomen heeft, en hun activiteitsterrein? Antwoord van de heer Mar(cid:14)·n namens de Commissie (12 december 1997) Het JEM-programma (uitwisselingsprogramma Junior EU-ASEAN managers) werd in 1996 gestart en in november 1996 volledig operationeel. Het geeft aan bedrijven van beide regio’s de kans om jong leidinggevend personeel van de partnerregio te ontvangen, waardoor een wederzijdse uitwisseling van professionele ervaring en cultuur mogelijk wordt. Sedert november 1996 werden in 19 bedrijven van 6 lidstaten drie groepen van jonge Aziatische bedrijfsleiders (14,17 en 10 deelnemers) ontvangen, respectievelijk in de sectoren handel, distributie, vervoer, elektronische systemen, energie en milieu. In januari-februari 1998 zullen eveneens ongeveer 15 jonge Europese bedrijfslei- ders naar Azie¤ en 15 jonge Aziatische bedrijfsleiders naar Europa worden gezonden in de distributie- en micro-elektronische sector voor Azie¤ en de distributie-, media- en banksector voor Europa. In dit eerste jaar dat het programma liep, zijn uitstekende resultaten geboekt; de deelnemende firma’s en de jonge bedrijfsleiders hebben op basis van deze ervaring werkelijk hun voldoening uitgesproken. Bovendien heeft de Commissie op grond hiervan een onafhankelijke adviseur belast met het opmaken van een eerste balans. (98/C 174/172) SCHRIFTELIJKE VRAAG P-3740/97 van Roberta Angelilli (NI) aan de Commissie (17 november 1997) Betreft: Milieueffectrapportage voor de aanleg van een tunnel onder de Engelenburcht in Rome Ik heb al enkele vragen gesteld over de aanleg van een tunnel onder de Engelenburcht in Rome. Recentelijk zijn er in de pers artikelen verschenen waarin de wethouder van Openbare Werken in Rome, gevraagd naar de wenselijkheid van een milieueffectrapportage voor deze tunnel overeenkomstig bijlage II van richtlijn 85/337/EEG (1), beweerde dat deze rapportage niet nodig zou zijn overeenkomstig de Italiaanse wet en vooral overeenkomstig de circulaire van 7 oktober 1996, nr. GAB/96/15208 van het Ministerie van Milieu. De Commissie heeft echter in andere gevallen laten weten dat wat de in Bijlage II van deze richtlijn genoemde projecten betreft het nodig is dat men zich houdt aan de D. P. R. van 12 april 1996 die een adequate omzetting blijkt te vormen van de principes van het Gemeenschapsrecht. Deze D. P. R. specificeert dat voor projecten als de tunnel de regio(cid:146)s moeten uitmaken of het nodig is een MER uit te voeren en hoe en volgens welke procedures dat dan wel moet gebeuren. In het geval van deze tunnel is deze kwestie nooit behandeld door de regio Latium die nog steeds geen regionale wet heeft uitgevaardigd om deze materie te regelen. Zo beschouwd blijken de opmerkingen van de wethouder over de ministerie¤le circulaire geheel ongegrond en lijkt het of de gemeente Rome onwettig heeft gehandeld toen zij geen MER heeft laten verrichten voor dit project, hoewel dit een terrein doorkruist dat archeologisch zeer belangrijk is en rijk aan monumenten


title: 1997 m. lapkričio 17 d. Tarybos sprendimas, suteikiantis išskirtinę finansinę pagalbą Armėnijai ir Gruzijai

eurovoc_concepts:
Armenia
EU aid
Georgia
economic support
financial aid
loan

text: 11/26 t. LT Europos Sąjungos oficialusis leidinys 353 31997D0787 L 322/37 EUROPOS BENDRIJŲ OFICIALUSIS LEIDINYS 1997 11 25 TARYBOS SPRENDIMAS 1997 m. lapkričio 17 d. suteikiantis išskirtinę finansinę pagalbą Armėnijai ir Gruzijai (97/787/EB) EUROPOS BENDRIJŲ TARYBA, atsižvelgdama į Europos bendrijos steigimo sutartį, ypač į jos 235 straipsnį, kadangi Bendrijos lengvatinėmis sąlygomis suteikiama finansinė pagalba ilgalaikių paskolų ir tiesioginių dotacijų pavidalu yra tin- kama priemonė šioje kritiškoje padėtyje atsidūrusioms pagalbą gaunančioms šalims; atsižvelgdama į Komisijos pasiūlymą (1), atsižvelgdama į Europos Parlamento nuomonę (2), kadangi ši pagalba paskolų ir dotacijų pavidalu yra suteikiama labai išimtinė ir jokiu būdu negali būti laikoma precedentu; kadangi Komisija, prieš pateikdama pasiūlymą, pasikonsultavo su Pinigų komitetu; kadangi sprendimas suteikti dotacijas teikiant šią pagalbą nepa- žeidžia biudžeto valdymo institucijos įgaliojimų; kadangi Armėnija ir Gruzija vykdo esmines politines ir ekonomi- nes reformas ir deda dideles pastangas rinkos ekonomikos mode- liui įdiegti; kadangi šią paramą turėtų tvarkyti Komisija; kadangi bus plėtojami prekybos, komerciniai ir ekonominiai ryšiai tarp Bendrijos, Armėnijos ir Gruzijos, įgyvendinant 1996 m. balandžio 22 d. jų pasirašytus atitinkamus partnerystės ir bend- radarbiavimo susitarimus; kadangi 1994 m. Armėnija ir Gruzija su Tarptautiniu valiutos fondu (TVF) susitarė dėl pirmos stabilizavimo ir politikos reformų priemonių grupės, kuri buvo remiama pagal TVF sisteminės per- tvarkos programą; kadangi 1995 m. birželio mėn. TVF valdyba patvirtino rezervinius susitarimus, remiančius vėlesnes ambicin- gas stabilizavimo ir struktūrinės pertvarkos reformas 1995 m. lie- pos mėn. –1996 m. birželio mėn. ; kadangi 1996 m. vasario mėn. TVF valdyba patvirtino Armėnijai išplėstinę trejų metų ir Gruzijai struktūrinės pertvarkos programą (ESAF), pakeičiančią dabarti- nius rezervinius susitarimus; lengvatinėmis sąlygomis kadangi Armėnijos ir Gruzijos valdžios institucijos oficialiai įsi- pareigojo visiškai vykdyti jų visus neįvykdytus finansinius įsipa- reigojimus Bendrijai; kadangi Sutartyje nenumatyta galimybė priimti šio sprendimo kitomis, nei numatyta 235 straipsnyje, sąlygomis, NUSPRENDĖ: 1 straipsnis 1. Bendrija Armėnijai pagalbą ilgalaikių paskolų ir tiesioginių dotacijų pavidalu. ir Gruzijai suteikia išskirtinę finansinę 2. Visa šia pagalba suteikiamų paskolų suma, kuri turi būti grą- žinta ne vėliau kaip per 15 metų ir kuriai taikomas 10 metų leng- vatinis terminas, neviršija 170 mln. ekiu. Dėl šios priežasties Komisija įgaliojama Bendrijos vardu skolinti reikiamas lėšas, kuriomis paskolų pavidalu naudojasi valstybės gavėjos. 3. Dotacijų suma 1997 m. sudaro 10 mln. ekiu ir 1998–2002 m. – 17 mln. ekiu per metus. Kasmetinės dotacijos suteikiamos, kadangi grynoji skola Bendrijai, kurią turi padengti valstybės gavėjos, buvo sumažinta bent jau panašia suma. kadangi minėtos institucijos pareiškė pageidavimą išskirtinei Bendrijos finansinei pagalbai gauti; 4. 2 ir 3 dalyse numatyta finansinė pagalba bus išmokėta valstybėms gavėjoms, su sąlyga, kad: kadangi Armėnijoje ir Gruzijoje pajamos mažos ir šiose šalyje yra ir susidariusios kritinės ekonominės ir socialinės aplinkybės; kadangi šioms šalims labai palankiomis sąlygomis gali būti sutei- kiamos paskolos iš Pasaulio banko ir TVF; (1) OL C 95, 1997 3 24, p. 64. (2) OL C 304, 1997 10 6, p. 39. a) šios valstybės bus visiškai įvykdžiusios visus esančius įsiparei- gojimus Bendrijai; b) šios valstybės patenkinamai įgyvendina plačią pertvarkos ir reformų programą, grindžiamą TVF programa. 5. Atsižvelgdama į esamus ir būsimus TVF susitarimus su valstybėmis gavėjomis, Bendrijos finansinę pagalbą tvarko Komi- sija, nuolatos konsultuodamasi su Pinigų komitetu. 354 LT Europos Sąjungos oficialusis leidinys 11/26 t. 2 straipsnis 1. Remiantis šio sprendimo nuostatomis, Komisija įgaliojama susitarti su valstybių gavėjų valdžios institucijomis dėl konkrečių pagalbos sumų ir terminų bei su šia pagalba siejamų sąlygų. 2. Komisija, pasikonsultavusi su Pinigų komitetu, tikrina, kaip valstybių gavėjų politikoje laikomasi tikslų ir šiuo sprendimu numatytos finansinės pagalbos teikimo sąlygų. 3 straipsnis 1. Su sąlyga kad buvo laikytasi 1 straipsnio 4 dalies nuostatų, visą paskolos sumą kartu su pirmuoju dotacijos įnašu 1997 m. išmoka Komisija. Vėliau, jei buvo laikytasi 1 straipsnio 4 dalies b punkto nuostatų, likusią pagalbos dotacijų dalį Komisija nuosekliai kas- met išmoka dalimis. 2. Lėšos išmokamos valstybių gavėjų centriniams bankams. 4 straipsnis 1. 1 straipsnyje minėtos skolinimosi ir skolinimo operacijos vyk- domos, remiantis ta pačia data vertei nustatyti. Dėl tų operacijų vykdymo Bendrijai nekyla rizika dėl terminų pakeitimo, valiutų kurso ar palūkanų normos svyravimų, arba bet kurio kito pobū- džio komercinė rizika. 2. Komisija garantuoja, kad į paskolos suteikimo sutarties termi- nus ir sąlygas bus įtraukta nuostata dėl priešlaikinio skolos grąži- nimo. 3. Valstybių gavėjų prašymu ir tais atvejais, kai aplinkybės leidžia pagerinti paskolų palūkanų normą, Komisija gali refinansuoti visas arba dalį jos pradinių skolinimųsi arba pakeisti atitinkamas finansines sąlygas. Vykdant refinansavimo arba restruktūrizavimo operacijas paisoma 1 dalyje nustatytų sąlygų. Tos operacijos neprailgina aptariamo skolinimosi vidutinio grąžinimo termino ir nepadidina skolinimosi tos dienos valiutos keitimo kursu, kapi- talo apimties refinansavimo ar restruktūrizavimo operacijų įvyk- dymo dieną. 4. Visas Bendrijos išlaidas, susijusias su susitarimų sudarymu ir operacijų vykdymu pagal šį sprendimą, apmoka valstybės gavėjos. 5. Pinigų komitetas bent kartą per metus yra informuojamas apie 2 ir 3 dalyse nurodytas operacijas. 5 straipsnis 1. Bent kartą per metus Komisija pateikia Europos Parlamentui ir Tarybai pranešimą apie šio sprendimo taikymą. 2. Iki 2002 m. gruodžio 31 d. Taryba, remdamasi išsamiu Komi- sijos pranešimu, tikrina, kaip iki tos dienos buvo taikomas šis sprendimas. Priimta Briuselyje, 1997 m. lapkričio 17 d. Tarybos vardu Pirmininkas J. -C. JUNCKER


title: ΓΡΑΠΤΗ ΕΡΩΤΗΣΗ αρ θ. 3807/97 του Ilona GRAENITZ προς την Επ τροπή. Αστική ευθύνη σε κοινοτικό επίπεδο για ατυχήματα σε πυρηνικά εργοστάσια παραγωγής ηλεκτρικής ενέργειας

eurovoc_concepts:
civil liability
degradation of the environment
indemnification
maritime transport
nuclear accident
nuclear energy
nuclear power station
public health
transport of dangerous goods

text: 25. 5. 98 EL Epi·shmh Efhmeri·da tvn Eyrvpai¤kv· n Koinoth·tvn C 158/191 H Genikh· Diey·uynsh thw Ispanikh·w Astynomi·aw ane·fere o·ti oi ene·rgeiew ayte·w e·ginan meta· apo· ai·thma poy ype·bale to syntonistiko· grafei·o tvn astynomikv· n yphresiv· n thw Eyrvpai¤kh·w (cid:201)nvshw gia th sygke·ntrvsh plhroforiv· n sxetika· me th sy·nuesh thw diadh·lvshw, th diadromh·, ta me·sa metafora·w kai ta kataly·mata poy e·xoyn problefuei· sto Loyjemboy·rgo. Se poia· nomikh· ba·sh sthri·zontai oi ene·rgeiew ayte·w; Uevrei· to Symboy·lio o·ti ei·nai symbate·w me to sebasmo· tvn uemelivdv· n eleyueriv· n o·pvw h eleyueri·a e·kfrashw kai to dikai·vma diadh·lvshw; Apa· nthsh (12 Febroyari·oy 1998) H th·rhsh thw dhmo·siaw ta·jhw sto e·dafow tvn kratv· n melv· n thw Eyrvpai¤kh·w (cid:146)Envshw empi·ptei sthn apokleistikh· armodio·thta tvn arxv· n ka·ue kra·toyw. To Symboy·lio den mporei· na la·bei ue·sh gia e·na zh·thma poy den anh·kei ston tome·a tvn armodioth·tvn poy toy pare·xoyn oi synuh·kew. (98/C 158/259) GRAPTH ERVTHSH P-3807/97 ypobolh· : Ilona Graenitz (PSE) prow thn Epitroph· (17 Noembri·oy 1997) Ue·ma: Astikh· eyuy·nh se koinotiko· epi·pedo gia atyxh·mata se pyrhnika· ergosta·sia paragvgh·w hlektrikh·w ene·rgeiaw Ta atyxh·mata kai dia·fora symba·nta se pyrhnika· ergosta·sia odhgoy·n se sobare·w bla·bew thw ygei·aw tvn anurv· pvn kauv· w kai thw epiba·rynshw toy periba·llontow. Gia na katastei· dynath· h oikonomikh· apozhmi·vsh tvn uyma·tvn kai gia na xrhmatodothuoy·n oi ergasi·ew apokata·stashw, ua h·tan epiuymhth· na yfi·statai astikh· eyuy·nh tvn epixeirh·sevn gia tiw syne·peiew poy proky·ptoyn apo· thn leitoyrgi·a tvn pyrhnikv· n ergostasi·vn. Kataba·llontai prospa·ueiew apo· tiw yphresi·ew saw gia thn proetoimasi·a eno·w no·moy sxetika· me thn y·parjh astikh·w eyuy·nhw se koinotiko· epi·pedo gia tiw epixeirh·seiw tvn pyrhnikv· n ergostasi·vn; Dieja·gontai sxetike·w syzhth·seiw gia to en lo·gv ue·ma kai se dieune·w epi·pedo; Apa·nthsh toy k. Papoytsh· ej ono· matow thw Epitroph· w (15 Dekembri·oy 1997) Sta prv· ta xro·nia thw pyrhnikh·w biomhxani·aw, ei·xe h·dh anagnvristei· o·ti h piuanh· e·ktash zhmiv· n apo· pyrhniko· aty·xhma h·tan te·toia, oy·tvw v· ste h asfalistikh· ka·lych thw eyuy·nhw se ue·mata pyrhnikh·w ene·rgeiaw apaitoy·se dieunh· synergasi·a. Ayto· epibebaiv· netai apo· ta dy·o dieunh· kauestv· ta poy die·poyn thn eyuy·nh tri·tvn se ue·mata pyrhnikh·w ene·rgeiaw, ta opoi·a anapty·xuhkan stiw arxe·w thw dekaeti·aw toy (cid:146)60, alla· kai me thn symperi·lhch toy a·ruroy 98 sthn Synuh·kh Eyrato·m. Stiw 29 Ioyli·oy 1960, h sy·mbash gia thn eyuy·nh tri·tvn ston tome·a thw pyrhnikh·w ene·rgeiaw (h Sy·mbash tvn Parisi·vn) synh·fuh ypo· thn aigi·da thw Orga·nvshw gia thn Oikonomikh· Synergasi·a kai Ana·ptyjh (OOSA) kai thn Yphresi·a Pyrhnikh·w Ene·rgeiaw, kai a·rxise na isxy·ei thn 1h Aprili·oy 1968. H sy·mbash ayth· kaly·ptei tiw perisso·terew dytikoeyrvpai¤ke·w xv· rew, symperilambanome·nvn o·lvn tvn kratv· n melv· n poy e·xoyn pro·gramma pyrhnikh·w ene·rgeiaw. Ypo· thn aigi·da toy Dieunoy·w Organismoy· Atomikh·w Energei·aw (DOAE), uespi·sthke stiw 21 Mai(cid:143)oy 1963 e·na oikoymeniko· kauestv· w sto plai·sio thw Sy·mbashw gia thn astikh· eyuy·nh o·son afora· tiw fuore·w apo· thn pyrhnikh· ene·rgeia (h Sy·mbash thw Bie·nnhw), poy ete·uh se isxy· stiw 4 Dekembri·oy 1974. To kauestv· w thw Sy·mbashw tvn Parisi·vn symplhrv· uhke apo· thn symplhrvmatikh· Sy·mbash gia thn eyuy·nh tri·tvn ston tome·a thw pyrhnikh·w ene·rgeiaw. H en lo·gv Sy·mbash synh·fuh stiw 31 Ianoyari·oy 1963. Oi Symba·seiw tvn Parisi·vn kai thw Bie·nnhw synde·uhkan stiw 21 Septembri·oy 1988 me·sv toy Koinoy· Prvtoko·lloy gia thn efarmogh· amfote·rvn tvn Symba·sevn. Oi uala·ssiew metafore·w pyrhnikv· n ylikv· n kaly·ptontai apo· th Sy·mbash thw 17hw Dekembri·oy 1971 sxetika· me thn astikh· eyuy·nh ston tome·a thw uala·ssiaw metafora·w pyrhnikv· n ylikv· n. Stiw 12 Septembri·oy 1997 uespi·sthke Prvto·kollo gia thn tropopoi·hsh thw Sy·mbashw thw Bie·nnhw. Me thn eykairi·a ayth· egkri·uhke epi·shw ne·o e·ggrafo, h Sy·mbash gia thn symplhrvmatikh· xrhmatodo·thsh. Ta e·ggrafa ayta·, ta opoi·a den e·xoyn ako·mh arxi·sei na isxy·oyn, ensvmatv· noyn tiw nomike·w, texnologike·w kauv· w kai oikonomike·w ejeli·jeiw poy e·xoyn shmeivuei· apo· thn sy·nach tvn Symba·sevn tvn Parisi·vn kai thw Bie·nnhw kai proble·poyn shmantike·w pro·suetew apozhmiv· seiw. Lo·gv thw periektikh·w fy·sevw toy dieunoy·w aytoy· kauestv· tow, h Epitroph· den uevrei· anagkai·a thn epejergasi·a eidikv· n nomouetikv· n diata·jevn gia thn Koino·thta. Sto plai·sio ayto·, ei·nai bebai·vw shmantiko· na ypogrammistei· o·ti h Synuh·kh Eyrato·m, kai eidiko·tera to a·ruro 98, den epiba·llei thn ue·spish nomouetikv· n diata·jevn ston sxetiko· tome·a


title: Rozhodnutí Rady ze dne 17. listopadu 1997 o rovnocennosti kontrol metod udržovacího šlechtění prováděných ve třetích zemích

eurovoc_concepts:
plant health control
seed
third country

text: 98 CS Úřední věstník Evropské unie 03/sv. 22 31997D0788 25. 11. 1997 ÚŘEDNÍ VĚSTNÍK EVROPSKÝCH SPOLEČENSTVÍ L 322/39 ROZHODNUTÍ RADY ze dne 17. listopadu 1997 o rovnocennosti kontrol metod udržovacího šlechtění prováděných ve třetích zemích (97/788/ES) RADA EVROPSKÉ UNIE, s ohledem na Smlouvu o založení Evropského společenství, směrnici s ohledem na dne 29. září 1970 o Společném katalogu odrůd druhů zeměděl- ských rostlin (1), a zejména na čl. 21 odst. 1 písm. b) této směrnice, 70/457/EHS Rady ze s ohledem na dne 29. září 1970 o uvádění osiva zeleniny na trh (2), a zejména na čl. 32 odst. 1 písm. b) této směrnice, 70/458/EHS směrnici Rady ze s ohledem na návrh Komise, rozhodnutím 92/420/EHS (3) Rada vzhledem k tomu, že konstatovala, že úřední kontroly metod udržovacího šlechtění prováděné v určitých třetích zemích poskytují stejné záruky jako kontroly prováděné členskými státy; že použitelnost uvedeného rozhodnutí skončila dne 30. června 1997; vzhledem k tomu, že výše zmíněné kontroly prováděné ve třetích zemích uvedených v rozhodnutí 92/420/EHS, i přes skutečnost, že bývalá Česká a slovenská federativní republika byla nahrazena Českou republikou a Slovenskou republikou, i nadále poskytují stejné záruky jako kontroly prováděné člen- skými státy; vzhledem k tomu, že v případě Korejské republiky uvedené ve výše zmíněném rozhodnutí byly požadovány dodatečné infor- mace; že dodatečné informace byly požadovány též po Svazové republice Jugoslávie; vzhledem k tomu, že je tudíž třeba poskytnout v případě těchto zemí kratší období rovnocennosti, aby byla zohledněna doba nezbytná pro dodání a ověření těchto informací; vzhledem k tomu, že v případě některých zemí prošetření podmínek, za kterých se úřední kontroly metod udržovacího šlechtění dalších druhů provádějí, ukázalo, že tyto kontroly poskytovaly stejné záruky jako kontroly prováděné členskými státy; vzhledem k tomu, že se zdá bezpředmětné prodloužit rovno- cennost udělenou pro Republiku Bosna a Hercegovina, protože zde není udržována žádná odrůda, která je v zájmu Společen- ství; vzhledem k tomu, že toto rozhodnutí nijak nebrání zrušit prohlášení Společenství o rovnocennosti nebo odmítnout prodloužení jeho platnosti, pokud podmínky pro jeho udělení nebyly splněny nebo přestaly být plněny; že za tím účelem je třeba získat další praktické informace o osivu odrůd udržova- ných v dotyčných třetích zemích při provádění srovnávacích testů Společenství; vzhledem k tomu, že určitá ustanovení technické a správní povahy v příloze mohou být často upravována; že pro zjedno- dušení postupů, jimiž se v současné době řídí změny přílohy, je třeba použít postup Stálého výboru pro osivo a sadbu v zemědělství, zahradnictví a lesnictví, PŘIJALA TOTO ROZHODNUTÍ: Článek 1 Úřední kontroly metod udržovacího šlechtění prováděné v zemích orgány vyjmenovanými v příloze u druhů uvede- ných ve směrnicích, jejichž seznam pro jednotlivé země příloha uvádí, poskytují stejné záruky jako kontroly prováděné člen- skými státy. Článek 2 technického Úpravy v příloze, a správního s výjimkou těch, které se týkají prvního sloupce tabulky, se přijímají postupem podle článku 23 směrnice 70/457/EHS a článku 40 směrnice 70/458/EHS. charakteru vzhledem k tomu, že je třeba rovnocennost poskytovanou těmto zemím rozšířit na tyto další druhy; Článek 3 (1) Úř. věst. L 225, 12. 10. 1970, s. 1. Směrnice naposledy pozměněná aktem o přistoupení z roku 1994. (2) Úř. věst. L 225, 12. 10. 1970, s. 7. Směrnice naposledy pozměněná směrnicí 96/72/ES (Úř. věst. L 304, 27. 11. 1996, s. 10). (3) Úř. věst. L 231, 13. 8. 1992, s. 22. se použije Toto rozhodnutí od 1. července 1997 do 30. června 1999 v případě Korejské republiky a Svazové republiky do a od 30. června 2002 v případě ostatních třetích zemí vyjmenova- ných v příloze. 1. července 1997 Jugoslávie 03/sv. 22 CS Úřední věstník Evropské unie 99 Toto rozhodnutí je určeno členským státům. Článek 4 V Bruselu dne 17. listopadu 1997. Za Radu předseda F. BODEN 100 CS Úřední věstník Evropské unie 03/sv. 22 PŘÍLOHA Orgán odpovědný za provádění kontrol Směrnice EHS Země (1) AR AU BG CA CH CL CZ Ministerio de Economia y Obras y Servicios Públicos Secretaría de Agricultura, Ganadería y Pesca Instituto Nacional de Semillas Buenos Aires Commonwealth Department of Primary Industries and Energy Canberra Semena i Possadchen Material Sofia Plant Products Division Division des Produits végétaux Nepean Ontario für Forschungsanstalt Landwirtschaftlichen Eidgenössische Pflanzenbau Reckenholz Zürich Station fédérale de recherches en production végétale de Chan- gins (RAC) Nyon Servicio Agrícola y Ganadero Departamento de Semillas Santiago Ústřední kontrolní a zkušební ústav zemědělský v Brně Odbor osiva a sadby Praha Central Institute for Supervising and Testing in Agriculture Department of seed testing Praha HR Bc Institute for Breeding and Production of Field Crops Zagreb HU IL Orszagos Mezogazdasagi Minosito Intézet National Institute for Agricultural Quality Control 1024 Budapest Ministry of Agriculture Plant Protection Services and Inspection PO Box 78 Bet-Dagan 50250 Israël 66/400 66/401 66/402 69/208 66/401 69/208 70/458 66/400 66/401 66/402 69/208 70/458 66/400 66/401 66/402 69/208 66/400 66/401 66/402 69/208 70/458 66/400 66/401 66/402 69/208 66/400 66/401 66/402 69/208 70/458 66/400 66/401 66/402 69/208 66/400 66/401 66/402 69/208 70/458 66/400 66/401 66/402 69/208 70/458 03/sv. 22 CS Úřední věstník Evropské unie 101 Země (1) JP KR MA NZ PL RO SI SK TW US UY YU Orgán odpovědný za provádění kontrol Ministry of Agriculture, Forestry and Fisheries 1-2-1 Kasumigaseki Chiyodaku Tokyo Ministry of Agriculture, Forestry and Fisheries Vegetables Division Seoul Ministère de l'agriculture et de la mise en valeur agricole Direction de la protection des végétaux des contrôles techni- ques et de la répression des fraudes Rabat Ministry of Agriculture Te Manatu Ahuwhenua Aotearoa MAF Regulatory Authority Wellington Inspekcja Nasienna Centralny Inspektorat Seed Inspection Service General Inspectorate Warszawa Ministry of Agriculture and Food Control and Inspections Department Bucharest Kmetijski Institut Slovenije Agricultural Institute of Slovenia Ljubljana Ústredný kontrolný a skúšobný ústav poľnohospodársky Bratislava Council of Agriculture, Food and Agriculture Department Taipei United States Department of Agriculture Agricultural Research Service Beltsville, Maryland Ministerio de Ganadería, Agricultura y Pesca Dirección General de Servicios Agronómicos Dirección Granos Unidad Ejecutora de Semillas Montevideo Savezno Ministarstvo za Poljoprivredu Federal Ministry of Agriculture Beograd Směrnice EHS 70/458 70/458 66/401 66/402 69/208 70/458 66/401 66/400 66/401 66/402 69/208 70/458 69/208 66/400 66/401 66/402 69/208 66/400 66/401 66/402 69/208 70/458 70/458 66/400 66/401 66/402 69/208 70/458 66/400 66/401 66/402 69/208 66/402 102 CS Úřední věstník Evropské unie 03/sv. 22 Země (1) ZA Orgán odpovědný za provádění kontrol Směrnice EHS Department of Agriculture Directorate of Plant and Quality Control Pretoria 66/401 66/402 69/208 (1) AR = Argentina AU = Austrálie BG = Bulharsko CA = Kanada CH = Švýcarsko CL = Chile CZ = Česká republika HR = Chorvatská republika HU = Maďarsko = Izrael IL JP = Japonsko KR = Korejská republika MA = Maroko NZ = Nový Zéland PL = Polsko RO = Rumunsko SI = Slovinská republika SK = Slovenská republika TW = Tchaj-wan US = Spojené státy americké UY = Uruguay YU = Svazová republika Jugoslávie ZA = Jihoafrická republika


title: Verordening (EG) nr. 2320/97 van de Raad van 17 november 1997 tot instelling van definitieve antidumpingrechten op de invoer van bepaalde naadloze buizen en pijpen van ijzer of van niet-gelegeerd staal, van oorsprong uit Hongarije, Polen, Rusland, de Tsjechische Republiek, Roemenië en de Slowaakse Republiek, tot intrekking van Verordening (EEG) nr. 1189/93 en tot beëindiging van de procedure met betrekking tot dergelijke invoer van oorsprong uit de Republiek Kroatië

eurovoc_concepts:
Central and Eastern Europe
anti-dumping duty
import
piping
tube

formats: html pdfa1b print


title: Decizia Consiliului din 17 noiembrie 1997 privind acordarea unei asistențe financiare excepționale Armeniei și Georgiei

formats: pdf print xhtml

text: 226 RO Jurnalul Oficial al Uniunii Europene 11/vol. 15 31997D0787 25. 11. 1997 JURNALUL OFICIAL AL COMUNITĂȚILOR EUROPENE L 322/37 DECIZIA CONSILIULUI din 17 noiembrie 1997 privind acordarea unei asistențe financiare excepționale Armeniei ș(cid:13)i Georgiei (97/787/CE) CONSILIUL UNIUNII EUROPENE, având în vedere Tratatul de instituire a Comunității Europene, în special articolul 235, întrucât această asistență financiară, fie că este vorba despre com- ponenta „împrumuturi” sau despre componenta „ajutoare nerambursabile (grant)”, este excepțională ș(cid:13)i, ca urmare, nu con- stituie un precedent pentru viitor; având în vedere propunerea Comisiei (1), având în vedere avizul Parlamentului European (2), întrucât Comisia a consultat Comitetul monetar înainte de a-ș(cid:13)i prezenta propunerea; întrucât Armenia ș(cid:13)i Georgia întreprind reforme politice ș(cid:13)i economice fundamentale ș(cid:13)i depun eforturi importante în vederea punerii în aplicare a unui model de economie de piață; întrucât includerea unei componente „ajutoare nerambursabile (grant)” în această asistență financiară nu aduce atingere competențelor autorității bugetare; întrucât asistența financiară trebuie gestionată de către Comisie; întrucât tratatul nu prevede, pentru adoptarea prezentei decizii, alte atribuții decât cele prevăzute la articolul 235, întrucât legăturile comerciale ș(cid:13)i economice se vor dezvolta între Comunitate, Armenia ș(cid:13)i Georgia în cadrul acordurilor lor de parteneriat ș(cid:13)i de cooperare respective, care s-au semnat la 22 apri- lie 1996; DECIDE: Articolul 1 întrucât Armenia ș(cid:13)i Georgia au convenit în 1994 cu Fondul Monetar Internațional (FMI) un prim pachet de măsuri de stabilizare ș(cid:13)i de reformă politică susținut de Facilitatea de Trans- formare Sistemică (FTS) a FMI; întrucât Consiliul de administrație al FMI a aprobat în iunie 1995 un acord stand-by în sprijinul reformelor ambițioase întreprinse în domeniul stabilizării ș(cid:13)i al ajustării structurale pentru perioada cuprinsă între iulie 1995 ș(cid:13)i iunie 1996; întrucât Consiliul de administrație al FMI a aprobat, în februarie 1996, acordarea Facilității de ajustare structurală extinsă (FASC) Armeniei ș(cid:13)i Georgiei, pe o durată de trei ani ș(cid:13)i în condiții privilegiate, prin înlocuirea acordurilor stand-by existente; întrucât autoritățile armene ș(cid:13)i georgiene s-au angajat în mod formal să achite integral toate obligațiile financiare existente față de Comunitate; întrucât aceste autorități au solicitat Comunității un sprijin finan- ciar excepțional; întrucât Armenia ș(cid:13)i Georgia sunt țări cu un venit mic, care se con- fruntă cu o situație economică ș(cid:13)i socială deosebit de critică; întru- cât aceste țări pot beneficia de împrumuturi acordate în condiții foarte favorabile de către Banca Mondială ș(cid:13)i FMI; întrucât asistența financiară acordată de către Comunitate în condiții preferențiale, sub formă de împrumuturi pe termen lung ș(cid:13)i de ajutoare nerambursabile (grant), este o măsură adecvată de ajutare a țărilor beneficiare în acest moment critic; (1) (2) JO C 95, 24. 3. 1997, p. 64. JO C 304, 6. 10. 1997, p. 39. (1) Comunitatea acordă Armeniei ș(cid:13)i Georgiei o asistență financi- ară excepțională sub formă de împrumuturi pe termen lung ș(cid:13)i de ajutoare nerambursabile (grant). (2) Componenta „împrumuturi” a acestei asistențe financiare se ridică la o valoare totală de maximum 170 de milioane de ECU pe o durată care nu poate depăș(cid:13)i 15 ani ș(cid:13)i cu un termen de grație de 10 ani. În acest scop, Comisia este împuternicită să ia împrumut, în numele Comunității Europene, resursele necesare, care vor fi puse la dispoziția țărilor beneficiare sub formă de împrumuturi. (3) Componenta „ajutoare nerambursabile (grant)” a acestei asis- tenței financiare constă într-o sumă anuală de 10 milioane de ECU pentru 1997 ș(cid:13)i de 17 milioane de ECU pe an pentru perioada 1998-2002. Ajutoarele nerambursabile (grant) anuale vor fi puse la dispoziție atât timp cât poziția debitoare netă a țărilor benefi- ciare față de Comunitate a fost redusă cu o sumă cel puțin echi- valentă. (4) Asistența financiară prevăzută la alineatele (2) ș(cid:13)i (3) se va vărsa țărilor beneficiare cu condiția: (a) ca acestea să se fi achitat de toate obligațiile față de Comuni- tate; (b) ca acestea să pună în aplicare în mod satisfăcător un program global de ajustare ș(cid:13)i de reforme în cadrul unui program sta- bilit de către FMI. (5) Asistența financiară a Comunității este gestionată de către Comisie în strânsă consultare cu Comitetul monetar ș(cid:13)i ținând seama de toate acordurile încheiate ș(cid:13)i care vor fi încheiate între FMI ș(cid:13)i țările beneficiare. 11/vol. 15 RO Jurnalul Oficial al Uniunii Europene 227 Articolul 2 (1) Sub rezerva dispozițiilor prezentei decizii, Comisia este împu- ternicită să convină cu autoritățile țărilor beneficiare în privința sumelor specifice, precum ș(cid:13)i a condițiilor aferente acestei asistențe financiare. (2) Comisia verifică, prin consultare cu Comitetul monetar, că politicile țărilor beneficiare respectă obiectivele ș(cid:13)i condițiile asis- tenței financiare prevăzute de prezenta decizie. Articolul 3 (1) Valoarea totală a împrumutului este pusă la dispoziție de către Comisie în 1997 în acelaș(cid:13)i timp cu prima tranș(cid:13)ă a ajutoare nerambursabile (grant), sub rezerva respectării condițiilor prevă- zute la articolul 1 alineatul (4). În continuare, restul componentei „ajutoare nerambursabile (grant)” este pus la dispoziție de către Comisie în tranș(cid:13)e anuale succesive, sub rezerva dispozițiilor articolului 1 alineatul (4) litera (b). (2) Fondurile se varsă la banca centrală din țările beneficiare. Articolul 4 (1) Operațiunile de luare ș(cid:13)i de dare cu împrumut prevăzute la articolul 1 se efectuează prin utilizarea aceleiaș(cid:13)i date a viramentului. Aceste operațiuni nu presupun pentru Comunitate nici transformarea scadențelor, nici riscul de schimb valutar sau al ratei dobânzii, nici un alt risc comercial. (2) Comisia se asigură că o clauză de rambursare anticipată este inserată în condițiile împrumutului. (3) La solicitarea țărilor beneficiare ș(cid:13)i în cazul în care circumstan- țele permit o reducere a ratei dobânzii pentru împrumuturi, Comi- sia poate refinanța integral sau parțial împrumuturile sale inițiale sau poate readapta condițiile financiare corespunzătoare. Opera- țiunile de refinanțare sau de readaptare sunt conforme cu condițiile prevăzute la alineatul (1). Aceste operațiuni nu pot avea ca efect prelungirea duratei medii a împrumuturilor în cauză sau mărirea valorii, exprimate la cursul de schimb curent, a capitalu- lui neachitat la data refinanțării sau a readaptării. (4) Toate costurile conexe angajate de către Comunitate pentru încheierea ș(cid:13)i executarea operațiunii prevăzute de prezenta decizie sunt în sarcina țărilor beneficiare. (5) Comitetul monetar este informat cu privire la toate operațiu- nile prevăzute la alineatele (2) ș(cid:13)i (3), cel puțin o dată pe an. Articolul 5 (1) Cel puțin o dată pe an, Comisia prezintă Parlamentului Euro- pean ș(cid:13)i Consiliului un raport privind punerea în aplicare a pre- zentei decizii. (2) Înainte de 31 decembrie 2002, Consiliul examinează punerea în aplicare a prezentei decizii până la această dată pe baza unui raport detaliat al Comisiei. Adoptată la Bruxelles, 17 noiembrie 1997. Pentru Consiliu Preș(cid:13)edintele J. -C. JUNCKER


title: Règlement (CE) nº 2287/97 de la Commission du 17 novembre 1997 concernant l'arrêt de la pêche du lieu noir par les navires battant pavillon du Royaume-Uni

eurovoc_concepts:
United Kingdom
catch quota
fishery management
fishing rights
sea fish
ship's flag


title: 97/796/EGKS, Euratom: Besluit van de Commissie van 17 november 1997 betreffende de sluiting, namens de Europese Gemeenschap voor Kolen en Staal en de Europese Gemeenschap voor Atoomenergie, van de Interim- overeenkomst betreffende de handel en aanverwante zaken tussen de Europese Gemeenschap, de Europese Gemeenschap voor Kolen en Staal en de Europese Gemeenschap voor Atoomenergie enerzijds en de Republiek Kirgizië anderzijds (Voor de EER relevante tekst)

eurovoc_concepts:
EAEC
ECSC
Kyrgyzstan
interim agreement (EU)
trade agreement


title: PREGUNTA ESCRITA n. 3808/97 del Ernesto CACCAVALE a la Comisión. Pérdida de fondos comunitarios

eurovoc_concepts:
EU initiative
EU programme
European Social Fund
fund (EU)
less-favoured region
operational programme
use of aid

text: C 158/192 ES Diario Oficial de las Comunidades Europeas 25. 5. 98 (98/C 158/260) PREGUNTA ESCRITA P-3808/97 de Ernesto Caccavale (UPE) a la Comisio·n (17 de noviembre de 1997) Asunto: Pe·rdida de fondos comunitarios Los PIC (Programas de Intere·s Comunitario) como «Horizon», «Adapt», «Now», «Youthstart», junto con el programa de emergencia para el empleo en el sur de Europa, son de gran importancia para las regiones del Objetivo 1. ¿Puede decir la Comisio·n: 1. si existe una fecha l(cid:14)·mite para la utilizacio·n de estos fondos, y cua·l es; de existir dicha fecha l(cid:14)·mite, si e·sta es prorrogable en caso de que no se hayan puesto en marcha los 2. programas; si el hecho de no haberlos puesto en marcha puede dar lugar a la pe·rdida de los fondos, especialmente en la 3. Regio·n de Campania? Respuesta del Sr. Flynn en nombre de la Comisio·n (15 de diciembre de 1997) 1. Por lo que respecta al programa operativo multirregional «Emergenza Occupazionale Sud», las iniciativas comunitarias Empleo y Adapt, el Fondo Social Europeo y el Estado miembro cofinancian acciones con arreglo a las condiciones establecidas en la Decisio·n comunitaria relativa a la asignacio·n de los recursos financieros, que se remite al Estado miembro. La Comisio·n, por lo que respecta al programa operativo multirregional, ha fijado para el per(cid:14)·odo 1994-1999 como fecha l(cid:14)·mite para realizar los compromisos el 31 de diciembre de 1999, y para la liquidacio·n de los pagos el 31 de diciembre de 2001. En cuanto al programa Adapt, se ha fijado como fecha l(cid:14)·mite para realizar los compromisos el 31 de diciembre de 1999, y para los pagos finales el 31 de diciembre de 2000. Por lo que se refiere al programa Empleo, se ha fijado como fecha l(cid:14)·mite para realizar los compromisos el 31 de diciembre de 1999, y para los pagos finales el 31 de diciembre de 2000. 2. Existe la posibilidad de renegociar estas fechas, previa solicitud debidamente justificada del Estado miembro y en el marco de la asociacio·n, pero, habida cuenta de la lejan(cid:14)·a de los plazos previstos, no se ha previsto en la actualidad ninguna modificacio·n de este tipo. Dado que el compromiso financiero se ha establecido sobre la totalidad del programa operativo, si no se iniciase alguna de las acciones no tendr(cid:14)·a ninguna consecuencia para los cre·ditos concedidos. 3. En este contexto, el Estado miembro es responsable de la aplicacio·n y seguimiento de las acciones, y para ello establece las modalidades a las que debera·n ajustarse los operadores en la realizacio·n de sus proyectos. En el caso de las iniciativas comunitarias, se trata de programas nacionales. As(cid:14)· pues, los comite·s de seguimiento de estos programas pueden en este caso proponer una reasignacio·n entre regiones en caso de no utilizacio·n de los recursos. (98/C 158/261) PREGUNTA ESCRITA E-3826/97 de Roberto Mezzaroma (UPE) a la Comisio·n (28 de noviembre de 1997) Asunto: Seguridad en Europa ¿Puede decir la Comisio·n si, por mor de la seguridad de la propia Europa, esta·n ella o el PE al corriente de la noticia aparecida en el perio·dico italiano «Il Giornale» de 10 de agosto de 1997 segu·n la cual una empresa de La Spezia y otra de Piacenza han suministrado a Libia maquinaria que permite alargar e intensificar el alcance de los misiles, lo que podr(cid:14)·a poner en peligro la paz en Oriente Pro·ximo y en las costas mediterra·neas de Europa? Respuesta del Sr. Van den Broek en nombre de la Comisio·n (18 de diciembre de 1997) La Comisio·n no tiene informacio·n sobre el posible suministro al que se refiere Su Sen(cid:152)or(cid:14)·a


title: REGULAMENTO (CE) Nº 2285/97 DA COMISSÃO de 17 de Novembro de 1997 que estabelece os valores forfetários de importação para a determinação do preço de entrada de certos frutos e produtos hortícolas

eurovoc_concepts:
agri-monetary policy
citrus fruit
fruit vegetable
grape
import price
pip fruit


title: 97/796/CECA, Euratom: Decisão da Comissão de 17 de Novembro de 1997 relativa à conclusão, em nome da Comunidade Europeia do Carvão e do Aço e da Comunidade Europeia da Energia Atómica, do Acordo Provisório sobre Comércio e Matérias Conexas entre, por um lado, a Comunidade Europeia, a Comunidade Europeia do Carvão e do Aço e a Comunidade Europeia da Energia Atómica e, por outro, a República do Quirguizistão (Texto relevante para efeitos do EEE)


title: Regolamento (CE) n. 2309/97 del Consiglio del 17 novembre 1997 che modifica il regolamento (CEE) n. 1765/92 che istituisce un regime di sostegno a favore dei coltivatori di taluni seminativi

eurovoc_concepts:
agricultural production policy
aid per hectare
durum wheat
land use
production aid